Epizyme analyst commentary at WedbushEpizyme price target raised to $25 from $20 at Wedbush. Wedbush analyst David Nierengarten raised his price target on Epizyme to $25 from $20, telling investors in a research note that abstracts from The European Hematology Association show responses are deepening in the EZH2-wt follicular lymphoma cohort, increasing his confidence that tazemetostat will find a broad use in FL regardless of mutation status. However, the analyst noted that he is "less certain" on the future for the drug in mesothelioma, where low response rates seen in a Phase 2 trial indicate a more challenging path forward.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. $EPZM, Epizyme, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.